Catherine Sebban

Summary

Affiliation: Institut Paoli-Calmettes
Country: France

Publications

  1. ncbi request reprint Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de
    Catherine Sebban
    Centre Leon Berard, 28 rue Laennec, 69008 Lyon, France
    Blood 108:2540-4. 2006
  2. doi request reprint Oral moxifloxacin or intravenous ceftriaxone for the treatment of low-risk neutropenic fever in cancer patients suitable for early hospital discharge
    Catherine Sebban
    Centre Leon Berard, 28 rue Laennec, Lyon, France
    Support Care Cancer 16:1017-23. 2008
  3. doi request reprint CD4 lymphopenia to identify end-of-life metastatic cancer patients
    Julien Peron
    Universite de Lyon, Lyon, France Université Lyon 1, Villeurbanne, France
    Eur J Cancer 49:1080-9. 2013
  4. doi request reprint Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study
    Gilles Salles
    Hospices Civils de Lyon and Université Lyon 1, Lyon, France
    Blood 112:4824-31. 2008
  5. doi request reprint Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study
    Catherine Sebban
    Centre Leon Berard, Lyon, France
    J Clin Oncol 26:3614-20. 2008
  6. ncbi request reprint [Prognostic factors for febrile neutropenia]
    Isabelle Ray-Coquard
    Centre Leon Berard, 28, rue Laennec, 69008 Lyon, France
    Bull Cancer 93:501-6. 2006
  7. doi request reprint Serum cytokines in follicular lymphoma. Correlation of TGF-β and VEGF with survival
    Sana Intidhar Labidi
    Department of Medical Oncology, Centre Leon Berard, Lyon, France
    Ann Hematol 89:25-33. 2010
  8. ncbi request reprint [Are antiangiogenic antibodies universal for solid tumor?]
    Isabelle Ray-Coquard
    Centre Leon Berard, 28, rue Laennec, 69008 Lyon
    Bull Cancer 94:S191-6. 2007
  9. ncbi request reprint CD4 lymphopenia as a risk factor for febrile neutropenia and early death after cytotoxic chemotherapy in adult patients with cancer
    Christophe Borg
    INSERM U590, Centre Leon Berard, Lyon, France
    Cancer 101:2675-80. 2004
  10. doi request reprint Evidence of time-dependent prognostic factors predicting early death but not long-term outcome in primary CNS lymphoma: a study of 91 patients
    Herve Ghesquieres
    Universite de Lyon, Centre Leon Berard, Department of Hematology, Lyon, France
    Hematol Oncol 31:57-64. 2013

Detail Information

Publications25

  1. ncbi request reprint Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de
    Catherine Sebban
    Centre Leon Berard, 28 rue Laennec, 69008 Lyon, France
    Blood 108:2540-4. 2006
    ..After long-term follow-up, our study showed that there was no statistically significant benefit in favor of first-line high-dose therapy in patients with follicular lymphoma. High-dose therapy should be reserved for relapsing patients...
  2. doi request reprint Oral moxifloxacin or intravenous ceftriaxone for the treatment of low-risk neutropenic fever in cancer patients suitable for early hospital discharge
    Catherine Sebban
    Centre Leon Berard, 28 rue Laennec, Lyon, France
    Support Care Cancer 16:1017-23. 2008
    ..Optimal management remains to be clearly defined, and new oral antibiotics need to be evaluated in this setting...
  3. doi request reprint CD4 lymphopenia to identify end-of-life metastatic cancer patients
    Julien Peron
    Universite de Lyon, Lyon, France Université Lyon 1, Villeurbanne, France
    Eur J Cancer 49:1080-9. 2013
    ..Cancer patients with CD4 lymphopenia have an increased risk of severe toxicity after administration of cytotoxic chemotherapy. The impact of CD4 lymphopenia on long term overall survival (OS) of cancer patients was explored in this work...
  4. doi request reprint Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study
    Gilles Salles
    Hospices Civils de Lyon and Université Lyon 1, Lyon, France
    Blood 112:4824-31. 2008
    ..This study's clinical trial was registered at the National Institutes of Health website as no. NCT00136552...
  5. doi request reprint Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study
    Catherine Sebban
    Centre Leon Berard, Lyon, France
    J Clin Oncol 26:3614-20. 2008
    ..The effect of these two strategies on the outcome of relapsing patients with follicular lymphoma has never been compared...
  6. ncbi request reprint [Prognostic factors for febrile neutropenia]
    Isabelle Ray-Coquard
    Centre Leon Berard, 28, rue Laennec, 69008 Lyon, France
    Bull Cancer 93:501-6. 2006
    ..Research in quantifying the risk of neutropenic complications may make it possible in the near future to target patients at greater risk with appropriate preventive strategies, thereby maximizing the benefits and minimizing the costs...
  7. doi request reprint Serum cytokines in follicular lymphoma. Correlation of TGF-β and VEGF with survival
    Sana Intidhar Labidi
    Department of Medical Oncology, Centre Leon Berard, Lyon, France
    Ann Hematol 89:25-33. 2010
    ..These results show the prognostic value of TGF-β and VEGF in follicular lymphoma and suggest their contribution to tumor microenvironment alterations...
  8. ncbi request reprint [Are antiangiogenic antibodies universal for solid tumor?]
    Isabelle Ray-Coquard
    Centre Leon Berard, 28, rue Laennec, 69008 Lyon
    Bull Cancer 94:S191-6. 2007
    ..This review article focuses on recent developments in the use of angiogenesis inhibitors for the treatment of breast, lung, and colorectal cancers...
  9. ncbi request reprint CD4 lymphopenia as a risk factor for febrile neutropenia and early death after cytotoxic chemotherapy in adult patients with cancer
    Christophe Borg
    INSERM U590, Centre Leon Berard, Lyon, France
    Cancer 101:2675-80. 2004
    ..Lymphopenia is frequently observed in patients with cancer and correlates with the risk of febrile neutropenia and early death after chemotherapy. The phenotype of the depleted lymphocyte populations was investigated in the current study...
  10. doi request reprint Evidence of time-dependent prognostic factors predicting early death but not long-term outcome in primary CNS lymphoma: a study of 91 patients
    Herve Ghesquieres
    Universite de Lyon, Centre Leon Berard, Department of Hematology, Lyon, France
    Hematol Oncol 31:57-64. 2013
    ..New prognostic factors predicting long-term outcome remain to be determined...
  11. pmc Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas
    Isabelle Ray-Coquard
    Université de Lyon Centre Léon Bérard, Department of Medical Oncology and EA SIS 4128, Lyon, France
    Cancer Res 69:5383-91. 2009
    ..48; 95% CI, 1.03-2.1) along with IPI. Our findings show that lymphopenia is an independent prognostic factor for overall and progression-free survival in several cancers...
  12. doi request reprint Utility of post-therapy brain surveillance imaging in the detection of primary central nervous system lymphoma relapse
    Gaelle Fossard
    Centre Leon Berard, Department of Hematology, Universite Claude Bernard Lyon 1, Lyon, France
    Eur J Cancer 72:12-19. 2016
    ..The goal of this study is to determine the utility of planned brain surveillance imaging in the detection of relapse in a retrospective cohort of PCNSL patients...
  13. doi request reprint Combination of rituximab with chemotherapy in diffuse large B-cell lymphoma. Evaluation in daily practice before and after approval of rituximab in this indication
    Herve Ghesquieres
    Service d Hematologie Clinique, Centre Leon Berard, Lyon, France
    Hematol Oncol 26:139-47. 2008
    ....
  14. doi request reprint Cost effectiveness of pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma: an economic evaluation of the PALM Trial
    Lionel Perrier
    Department Cancer and Environment, Cancer Centre Léon Bérard, University of Lyon, GATE Lyon St Etienne, UMR CNRS 5824, 28 rue Laennec, 69373, Lyon Cedex 08, France
    Appl Health Econ Health Policy 11:129-38. 2013
    ..To our knowledge, no cost-effectiveness analysis (CEA) of pegfilgrastim in this setting has been published yet...
  15. pmc Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte
    Bertrand Coiffier
    Hospices Civils de Lyon and Université Lyon 1, Lyon, France
    Blood 116:2040-5. 2010
    ..The results from the 10-year analysis confirm the benefits and tolerability of the addition of rituximab to CHOP. Our findings underscore the need to treat elderly patients as young patients, with the use of curative chemotherapy...
  16. doi request reprint Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial
    Bertrand Coiffier
    Hematology, Hospices Civils de Lyon, Lyon, France
    Lancet Oncol 12:773-84. 2011
    ..We compared the efficacy and safety of rituximab alone or combined with bortezomib in patients with relapsed or refractory follicular lymphoma in a phase 3 setting...
  17. doi request reprint Hepatic veno-occlusive disease after tandem autologous stem cell transplantation conditioned by melphalan
    Sana Intidhar Labidi
    Department of Medical Oncology, Centre Leon Berard, Lyon, France
    Int J Hematol 88:291-3. 2008
    ..The patient received defibrotide with total recovery. The occurence of HVOD after conditioning by melphalan is uncommon and the role of bortezomib was questioned...
  18. doi request reprint Impact of the introduction of rituximab in first-line follicular lymphoma: a retrospective study of 247 unselected patients referred to a single institution with a long-term follow-up
    Emmanuelle Nicolas-Virelizier
    Hematology Department, Centre Leon Berard, Lyon, France
    Hematol Oncol 33:1-8. 2015
    ..These data from everyday practice confirm the benefit for patients with FL treated in the last decade through availability of rituximab in first line used alone or in association with various chemotherapy regimens...
  19. pmc Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma
    Carrie A Thompson
    Carrie A Thompson, Matthew J Maurer, James R Cerhan, Stephen M Ansell, David J Inwards, Patrick B Johnston, William R Macon, Ivana N Micallef, Grzegorz S Nowakowski, Luis F Porrata, Thomas E Witzig, Thomas M Habermann, Mayo Clinic, Rochester, MN Herve Ghesquieres, Pierre Biron, Catherine Chassagne Clément, Thérèse Gargi, Emmanuelle Nicolas Virelizier, Marie Peix, Catherine Sebban, Centre Leon Berard, University of Lyon, Lyon, France George J Weiner and Brian K Link, University of Iowa, Iowa City, IA
    J Clin Oncol 32:3506-12. 2014
    ....
  20. ncbi request reprint [Anemia and chemotherapy]
    Isabelle Ray-Coquard
    Centre Leon Berard, 28, rue Laennec, 69008 Lyon
    Bull Cancer 90:S133-43. 2003
    ..In addition, anemia could relieve of specific treatment such as blood transfusion or preventive treatment with recombinant erythropoietin...
  21. doi request reprint Use of F-18 FDG PET/CT in non-Hodgkin lymphoma with central nervous system involvement
    Sebastien Cimarelli
    Departement de Medecine Nucleaire, Centre Leon Berard, Universite de Lyon, Lyon, France
    Clin Nucl Med 36:e45-9. 2011
    ..Metabolic imaging seems to be complementary to conventional imaging techniques for the extent-of-disease evaluation and therapy monitoring of CNS lesions...
  22. doi request reprint Clinical characteristics and outcome of isolated extracerebral relapses of primary central nervous system lymphoma: a case series
    Sawyna Provencher
    Department of Medical Oncology, Centre Leon Berard, Universite de Lyon, Lyon, France
    Hematol Oncol 29:10-6. 2011
    ..Patient follow-up must be prolonged because systemic relapse can occur as late as 10 years after initial diagnosis. Whether EC relapses of PCNSL have a better prognosis than CNS relapses needs to be assessed in a larger cohort...
  23. doi request reprint Etoposide pharmacokinetics impact the outcomes of lymphoma patients treated with BEAM regimen and ASCT: a multicenter study of the LYmphoma Study Association (LYSA)
    Benoit You
    EMR UCBL HCL 3738, Faculté de médecine Lyon Sud, Universite Lyon 1, Lyon, France
    Cancer Chemother Pharmacol 76:939-48. 2015
    ..The clinical impact of PK variations of etoposide high doses has never been explored in lymphoma patients...
  24. ncbi request reprint Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)
    Nicolas Mounier
    Service d Onco Hématologie, INSERM ERM0220 Hôpital Saint Louis, AP HP, Paris, France
    Blood 101:4279-84. 2003
    ..These results suggest that rituximab is able to prevent chemotherapy failure in patients with bcl-2 protein overexpression...
  25. ncbi request reprint Smoking and non-Hodgkin's lymphoma: a case-control study in the Rhône-Alpes region of France
    Herve Besson
    International Agency for Research on Cancer, 150 cours Albert Thomas, 69378 Lyon cedex 8, France
    Cancer Causes Control 14:381-9. 2003
    ..To study the relation between smoking and non-Hodgkin's lymphoma (NHL), in the Rhône-Alpes region of France...